Journal Article10.1016/S0968-0004(97)01155-9
A good antisense molecule is hard to find
TL;DR: To minimize unwanted non-antisense effects, investigators are searching for antisense compounds and ribozymes whose target sites are particularly vulnerable to attack.
read more
About: This article is published in Trends in Biochemical Sciences. The article was published on 01 Feb 1998.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
MDM2-specific antisense oligonucleotides
Jiandong Chen,Sudhir Agrawal,Ruiwen Zhang +2 more
- 18 Aug 1998
TL;DR: In this article, the authors proposed a method to activate tumor suppressors using an antisense oligonucleotide complementary to a portion of the MDM2-encoding RNA.
60
Selection of genetic agents from random peptide aptamer expression libraries.
TL;DR: This chapter describes how to obtain and characterize peptide aptamers for both the reverse and forward analysis of cellular processes.
60
Patent
Compositions and their uses directed to huntingtin
Susan M. Freier
- 26 Jan 2007
TL;DR: In this article, compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal were presented, along with uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
60
Patent
Antisense modulation of acyl coa cholesterol acyltransferase-2 expression
Rosanne M. Crooke,Mark J. Graham,Kristina Lemonidis Tarbet +2 more
- 15 Jul 2002
TL;DR: Antisense compounds, compositions and methods for modulating the expression of acyl CoA cholesterol acyltransferase-2 are provided in this article, which includes antisense compounds particularly antisense oligonucleotides, targeted to nucleic acids encoding acyl coA cholesterol ACyltransfer enzyme-2.
59
Patent
Pharmaceutical composition for treatment of duchenne muscular dystrophy
Masafumi Matsuo
- 16 Aug 2001
TL;DR: In this paper, a therapeutic pharmaceutical composition for patients of Duchenne muscular dystrophy with entire loss of exon 20 in dystrophin mature mRNA is provided, which comprise as an active principle an antisense oligonucleotide consisting of a 20 to 50-nucleotide sequence against exon 19 of the dyStrophin pre-mRNA.
58
References
Quantitative monitoring of gene expression patterns with a complementary DNA microarray.
TL;DR: A high-capacity system was developed to monitor the expression of many genes in parallel by means of simultaneous, two-color fluorescence hybridization, which enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA.
10.9K
Cpg motifs in bacterial dna trigger direct b-cell activation
Arthur M. Krieg,Ae-Kyung Yi,Sara Matson,Thomas J. Waldschmidt,Gail A. Bishop,Gail A. Bishop,Rebecca M. Teasdale,Gary A. Koretzky,Dennis M. Klinman +8 more
TL;DR: The potent immune activation by CpG oligon nucleotides has impli-cations for the design and interpretation of studies using 'antisense' oligonucleotides and points to possible new applications as adjuvants.
3.9K
Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Cy A. Stein,Yung-Chi Cheng +1 more
TL;DR: The potential use of phosphorothioate oligos as inhibitors of viral replication is highlighted and these are examples of oligos that are being considered for clinical therapeutic trials and meet some, but not all, of these criteria.
1.5K
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C- raf kinase
TL;DR: It is suggested that antisense inhibitors targeted against C–raf–1 kinase may be of considerable value as antineoplastic agents that display activity against a wide spectrum of tumor types at well–tolerated doses.
511
Selecting effective antisense reagents on combinatorial oligonucleotide arrays.
TL;DR: An array of 1,938 oligodeoxynucleotides was fabricated on the surface of a glass plate and used to measure the potential of oligonucleotide for heteroduplex formation with rabbit β-globin mRNA, finding no obvious features in the mRNA sequence or the predicted secondary structure that can explain the variation in heterod uplex yield.
404